$CRVO
CervoMed Inc. Stock $crvo

$crvo Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000105369117000015 Filed on May 15, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.550M	$3.860M
YoY Change	-59.84%	739.13%
% of Gross Profit
Research & Development	$1.008M	$2.353M
YoY Change	-57.18%	221.46%
% of Gross Profit
Depreciation & Amortization	$6.603K	$10.00K
YoY Change	-33.97%
% of Gross Profit
Operating Expenses	$1.008M	$2.353M
YoY Change	-57.18%	221.46%
Operating Profit	-$2.567M	-$6.223M
YoY Change	-58.75%	421.78%
Interest Expense	$55.72K	$21.00
YoY Change	265228.57%	-99.96%
% of Operating Profit
Other Income/Expense, Net	-$13.10M
YoY Change
Pretax Income	-$28.64M	-$6.220M
YoY Change	360.45%	401.61%
Income Tax
% Of Pretax Income
Net Earnings	-$28.64M	-$6.223M
YoY Change	360.2%	400.46%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$41.51M	-$9.284M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.21M	$5.870M
YoY Change	108.01%	-69.44%
Cash & Equivalents	$12.21M	$5.866M
Short-Term Investments
Other Short-Term Assets	$140.0K	$390.0K
YoY Change	-64.1%	-78.21%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$20.63M	$6.251M
YoY Change	230.06%	-70.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$79.52K	$103.7K
YoY Change	-23.29%	-13.61%
Goodwill	$6.929M	$7.105M
YoY Change	-2.47%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$63.82K	$134.3K
YoY Change	-52.47%
Total Long-Term Assets	$15.71M	$16.66M
YoY Change	-5.69%	-10.53%
TOTAL ASSETS
Total Short-Term Assets	$20.63M	$6.251M
Total Long-Term Assets	$15.71M	$16.66M
Total Assets	$36.34M	$22.91M
YoY Change	58.63%	-42.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$557.6K	$1.120M
YoY Change	-50.21%	273.29%
Accrued Expenses	$1.020M	$1.090M
YoY Change	-6.42%	-39.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.880M	$0.00
YoY Change
Total Short-Term Liabilities	$51.60M	$2.208M
YoY Change	2237.36%	5.63%
LONG-TERM LIABILITIES
Long-Term Debt	$550.0K	$550.0K
YoY Change	0.0%
Other Long-Term Liabilities	$33.31K	$37.77K
YoY Change	-11.82%
Total Long-Term Liabilities	$33.31K	$37.77K
YoY Change	-11.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$51.60M	$2.208M
Total Long-Term Liabilities	$33.31K	$37.77K
Total Liabilities	$55.46M	$6.332M
YoY Change	775.86%	44.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$88.83M	-$48.38M
YoY Change	83.62%
Common Stock	$69.71M	$64.95M
YoY Change	7.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$19.12M	$16.58M
YoY Change
Total Liabilities & Shareholders Equity	$36.34M	$22.91M
YoY Change	58.63%	-42.17%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$28.64M	-$6.223M
YoY Change	360.2%	400.46%
Depreciation, Depletion And Amortization	$6.603K	$10.00K
YoY Change	-33.97%
Cash From Operating Activities	-$3.416M	-$4.630M
YoY Change	-26.23%	393.21%
INVESTING ACTIVITIES
Capital Expenditures	$6.372K	$1.994K
YoY Change	219.56%	-8.66%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$8.500M
YoY Change	-100.0%	240.0%
Cash From Investing Activities	-$6.372K	$8.499M
YoY Change	-100.07%	240.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	14.08M	$0.00
YoY Change
NET CHANGE
Cash From Operating Activities	-3.416M	-$4.630M
Cash From Investing Activities	-6.372K	$8.499M
Cash From Financing Activities	14.08M	$0.00
Net Change In Cash	10.66M	$3.868M
YoY Change	175.54%	148.13%
FREE CASH FLOW
Cash From Operating Activities	-$3.416M	-$4.630M
Capital Expenditures	$6.372K	$1.994K
Free Cash Flow	-$3.422M	-$4.632M
YoY Change	-26.12%	392.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001053691
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10345637	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	Diffusion Pharmaceuticals Inc.
CY2017Q1	dei	Trading Symbol TradingSymbol	dffn
CY2016Q4	dffn	Accrued Clinical Studies Expenses Current AccruedClinicalStudiesExpensesCurrent	220978	USD
CY2017Q1	dffn	Accrued Clinical Studies Expenses Current AccruedClinicalStudiesExpensesCurrent	346861	USD
CY2017Q1	dffn	Convertible Preferred Stock Numberof Votesper Share ConvertiblePreferredStockNumberofVotesperShare	0.50627	vote_per_share
CY2017Q1	dffn	Convertible Preferred Stock Numberof Votesper Share ConvertiblePreferredStockNumberofVotesperShare	0.84874	vote_per_share
CY2016Q1	dffn	Depreciation Depletion And Amortization Including Discontinued Operations DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations	7853	USD
CY2017Q1	dffn	Depreciation Depletion And Amortization Including Discontinued Operations DepreciationDepletionAndAmortizationIncludingDiscontinuedOperations	6603	USD
CY2017Q1	dffn	Fair Value Assumptions Stock Price FairValueAssumptionsStockPrice	2.38
CY2016Q1	dffn	Noncashor Part Noncash Transaction Reclassificationof Deferred Offering Costs NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts	0	USD
CY2017Q1	dffn	Noncashor Part Noncash Transaction Reclassificationof Deferred Offering Costs NoncashorPartNoncashTransactionReclassificationofDeferredOfferingCosts	180456	USD
CY2016Q1	dffn	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	0	USD
CY2017Q1	dffn	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	178258	USD
CY2016Q4	dffn	Prepaid Expenses Deposits And Other Assets PrepaidExpensesDepositsAndOtherAssets	50844	USD
CY2017Q1	dffn	Prepaid Expenses Deposits And Other Assets PrepaidExpensesDepositsAndOtherAssets	138986	USD
CY2016Q1	dffn	Proceeds From Reverse Merger Transaction ProceedsFromReverseMergerTransaction	8500602	USD
CY2017Q1	dffn	Proceeds From Reverse Merger Transaction ProceedsFromReverseMergerTransaction	0	USD
CY2017Q1	dffn	Temporary Equity Issuance Costs TemporaryEquityIssuanceCosts	2400000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	557629	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	72855	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	185163	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	399740	USD
CY2017Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	135072	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	69363575	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	69700264	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	28017	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	366383	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	USD
CY2017Q1	dffn	Temporary Equity Offering Costs TemporaryEquityOfferingCosts	500000	USD
CY2017Q1	dffn	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	12376329	shares
CY2016Q1	dffn	Warrant Expenseand Fair Value Adjustmentof Warrant Liability WarrantExpenseandFairValueAdjustmentofWarrantLiability	0	USD
CY2017Q1	dffn	Warrant Expenseand Fair Value Adjustmentof Warrant Liability WarrantExpenseandFairValueAdjustmentofWarrantLiability	26015746	USD
CY2017Q1	dffn	Warrant Expenseand Fair Value Adjustmentof Warrant Liability WarrantExpenseandFairValueAdjustmentofWarrantLiability	26000000	USD
CY2017Q1	dffn	Warrant Related Expense WarrantRelatedExpense	10200000	USD
CY2016Q1	dffn	Warrant Related Expense WarrantRelatedExpense	0	USD
CY2017Q1	dffn	Warrant Related Expense WarrantRelatedExpense	10225846	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1684158	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	393471	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	366383	USD
CY2016Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3383	USD
CY2017Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	57185	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2715984	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29471085	shares
CY2016Q4	us-gaap	Assets Assets	17484384	USD
CY2017Q1	us-gaap	Assets Assets	36343543	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	1603696	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	20631946	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1997192	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5865611	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1552852	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12212025	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3868419	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	10659173	USD
CY2017Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.22
CY2017Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1	shares
CY2017Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14016608	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2017Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	550000	USD
CY2017Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2430000	USD
CY2017Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1880000	USD
CY2016Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0	USD
CY2016Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	711495	USD
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10345637	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10345637	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10345637	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10345637	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	10346	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	10346	USD
CY2016Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1880000	USD
CY2017Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1880000	USD
CY2016Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	550000	USD
CY2017Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	550000	USD
CY2017Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2017Q1	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	-28000	USD
CY2016Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	200000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3279363	USD
CY2017Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3279363	USD
CY2016Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	7853	USD
CY2017Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	6603	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2017Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	48145520	USD
CY2016Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	USD
CY2017Q1	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	59000	USD
CY2017Q1	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	58845	USD
CY2017Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	58845	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.62
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.78
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2900000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P5Y310D
CY2016Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	12919674	USD
CY2017Q1	us-gaap	Fair Value Assumptions Exercise Price FairValueAssumptionsExercisePrice	2.22
CY2017Q1	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y
CY2017Q1	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	1.270
CY2017Q1	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.021
CY2017Q1	us-gaap	Fair Value Assumptions Weighted Average Expected Dividend FairValueAssumptionsWeightedAverageExpectedDividend	0
CY2016Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	21261000	USD
CY2017Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8639000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8639000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3862484	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1553139	USD
CY2017Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	90000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	6929258	USD
CY2017Q1	us-gaap	Goodwill Goodwill	6929258	USD
CY2017Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	797827	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1123303	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	97058	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	99737	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	21	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	55719	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	29359	USD
CY2017Q1	us-gaap	Interest Payable Current InterestPayableCurrent	57173	USD
CY2016Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	487500	USD
CY2017Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28697623	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6223144	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2567313	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	575470	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	118519	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	116464	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6372	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4630189	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3415901	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-6223165	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-28638778	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6223165	USD
CY2016Q4	us-gaap	Liabilities Liabilities	8299700	USD
CY2017Q1	us-gaap	Liabilities Liabilities	55462082	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17484384	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36343543	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4438422	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	51599412	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14081446	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8498608	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	114409	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	112354	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	39735	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	73989	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	874264	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1016263	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	232675	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	63815	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	31915	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	33307	USD
CY2016Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
CY2017Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	2870226	USD
CY2016Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	151332	USD
CY2017Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	233149	USD
CY2016Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2017Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	187649	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1994	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6372	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	14269095	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79755	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	79524	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2352807	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1007571	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60189237	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-88829149	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	393471	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	366383	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.252
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1548216	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.04
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1461	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	98184	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2207409	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2304132	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.09
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.84
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	15.00
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.33
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y281D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y10M24D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2016Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2017Q1	us-gaap	Stock Issued1 StockIssued1	8280935	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	9184684	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	-19118539	USD
CY2016Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2017Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2016Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2017Q1	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	58845	USD
CY2017Q1	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	25000000	USD
CY2017Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2017Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	13750000	shares
CY2016Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2017Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	12376329	shares
CY2016Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2017Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	12376329	shares
CY2016Q4	us-gaap	Temporary Equity Shares Subscribed But Unissued Subscriptions Receivable TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable	0	USD
CY2017Q1	us-gaap	Temporary Equity Shares Subscribed But Unissued Subscriptions Receivable TemporaryEquitySharesSubscribedButUnissuedSubscriptionsReceivable	8280935	USD
CY2017Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	0	USD
CY2016Q4	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	0.001	USD
CY2017Q1	us-gaap	Temporary Equity Value Excluding Additional Paid In Capital TemporaryEquityValueExcludingAdditionalPaidInCapital	0.001	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9996381	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10337726	shares
CY2017Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td style="width:621px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Organization and Description of Business</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diffusion Pharmaceuticals Inc. (“Diffusion” or the “Company”), a Delaware Corporation, is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, trans sodium crocetinate (“TSC”), uses a novel mechanism to re-oxygenate the microenvironment of solid cancerous tumors, thereby enhancing tumor cells’ response to conventional treatment without additional side effects. TSC has received orphan drug designations for the treatment of glioblastoma multiforme (“GBM”) and metastatic brain cancer. The Company expects to enter a Phase III study in newly diagnosed GBM patients in the next twelve months.</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 8, 2016, the Company completed a reverse merger (the Merger") with RestorGenex Corporation (“RestorGenex”) whereby the Company was considered the acquirer for accounting purposes. The operational activity of RestorGenex is included in the Company’s consolidated financial statements from the date of acquisition. Accordingly, all comparative period information presented in these unaudited condensed consolidated financial statements from January 1, 2016 through January 7, 2016 exclude any activity related to RestorGenex.</font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:58px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the unaudited condensed consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited condensed consolidated financial statements in the period they are determined necessary. </font></div></div>

Files In Submission

Name	View Source	Status
0001053691-17-000015-index-headers.html	Edgar Link	pending
0001053691-17-000015-index.html	Edgar Link	pending
0001053691-17-000015.txt	Edgar Link	pending
0001053691-17-000015-xbrl.zip	Edgar Link	pending
dffn-20170331.xml	Edgar Link	completed
dffn-20170331.xsd	Edgar Link	pending
dffn-20170331_cal.xml	Edgar Link	unprocessable
dffn-20170331_def.xml	Edgar Link	unprocessable
dffn-20170331_lab.xml	Edgar Link	unprocessable
dffn-20170331_pre.xml	Edgar Link	unprocessable
dffn2017033110-q.htm	Edgar Link	pending
dffn20170331ex311.htm	Edgar Link	pending
dffn20170331ex312.htm	Edgar Link	pending
dffn20170331ex321.htm	Edgar Link	pending
dffn20170331ex322.htm	Edgar Link	pending
dffn20170331ex42registrati.htm	Edgar Link	pending
diffusion.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lease1317carltonaveste400fu.htm	Edgar Link	pending
lease1317exa.jpg	Edgar Link	pending
lease1317img2.jpg	Edgar Link	pending
lease1317sig2.jpg	Edgar Link	pending
lease1317sig3.jpg	Edgar Link	pending
lease1317sig4.jpg	Edgar Link	pending
lease1317signature.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRVO
CervoMed Inc. Stock $crvo

2017 Q1 Form 10-Q Financial Statement

#000105369117000015 Filed on May 15, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRVO CervoMed Inc. Stock $crvo

2017 Q1 Form 10-Q Financial Statement

#000105369117000015 Filed on May 15, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRVO
CervoMed Inc. Stock $crvo